DUBLIN, Oct. 20, 2020 The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report has been added to ResearchAndMarkets.coms offering.

This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2014.

There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all joint venture deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.

Key benefits

Available deals and contracts are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in joint venture partnerships2.1. Introduction2.2. Definition of joint venture deals2.3. Success factors for joint venture partnerships2.4. When joint venture partnerships can be useful2.5. Attributes of joint venture partnerships2.6. Aligning partners to make the joint venture work2.7. Trends in joint venture partnerships since 20142.7.1. Joint venture dealmaking by year, 2014 to 20202.7.2. Joint venture dealmaking by stage of development 2014 to 20202.7.3. Joint venture dealmaking by industry sector 2014 to 20202.7.4. Joint venture dealmaking by therapy area, 2014 to 20202.7.5. Joint venture dealmaking by technology type, 2014 to 20202.7.6. Joint venture dealmaking by most active company, 2014 to 20202.8. The future of joint venture partnerships

Chapter 3 Overview of joint venture deal structure3.1. Introduction3.2. Joint venture agreement structure3.3. Example joint venture agreements3.3.1. Case study 1: Agila Specialties Pfenex3.3.2. Case study 2: Dance Biopharm Harmony Asset

Chapter 4 Leading joint venture deals4.1. Introduction4.2. Top joint venture deals by value

Chapter 5 Top 25 most active active joint venture dealmakers5.1. Introduction5.2. Top 25 most active joint venture dealmakers

Chapter 6 Joint venture deals including contracts directory6.1. Introduction6.2. Joint venture deals with contracts 2014 to 2020

AppendicesAppendix 1 Joint venture dealmaking by companies A-ZAppendix 2 Joint venture dealmaking by industry sectorAppendix 3 Joint venture dealmaking by stage of developmentAppendix 4 Joint venture dealmaking by therapy areaAppendix 5 Joint venture dealmaking by technology typeAppendix 6 Joint venture referencesAppendix 7 ResourcesAppendix 8 Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/b8myyj

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Follow this link:
Latest Joint Venture Agreements Announced in the Pharmaceutical, Biotechnology and Diagnostic, 2020 - Virtual-Strategy Magazine